NBIX Stock Analysis: Neurocrine Biosciences | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 18.652m USD | 12M Return: 30.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 200M
EPS Trend: 86.2%
Qual. Beats: 2
Rev. Trend: 99.4%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Neurocrine Biosciences is a US-based biopharmaceutical company that discovers, develops, and commercializes prescription drugs targeting neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. Founded in 1992 and headquartered in San Diego, California, the company operates within the large-cap biotechnology segment of the healthcare sector.
The company markets a portfolio of branded products including INGREZZA for tardive dyskinesia and Huntingtons disease-associated chorea, Orilissa and Oriahnn for endometriosis and uterine fibroids respectively, and CRENESSITY, ALKINDI, and Efmody for endocrine conditions such as congenital adrenal hyperplasia. Its clinical pipeline spans multiple therapeutic areas, with candidates in development for movement disorders, major depressive disorder, schizophrenia, bipolar mania, Alzheimers disease, epilepsy, obesity, and related metabolic diseases.
Neurocrine supplements its internal R&D with a network of license and collaboration agreements with major pharmaceutical partners including Takeda Pharmaceutical, Sanofi, AbbVie, Xenon Pharmaceuticals, Voyager Therapeutics, Nxera Pharma, and Tanabe Pharma. This hybrid model of in-house development combined with external partnerships is typical among mid-to-large biotech firms seeking to expand pipeline reach while sharing development risk.
- INGREZZA revenue growth drives tardive dyskinesia market expansion
- CRENESSITY commercial launch targets congenital adrenal hyperplasia
- Pipeline catalyst: osavampator Phase 3 for major depressive disorder
| Net Income: 705.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 2.65 > 1.0 |
| NWC/Revenue: 22.61% < 20% (prev 47.91%; Δ -25.30% < -1%) |
| CFO/TA 0.17 > 3% & CFO 898.1m > Net Income 705.5m |
| Net Debt (12.0m) to EBITDA (817.5m): 0.01 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.2m) vs 12m ago 3.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 72.96% > 50% (prev 64.53%; Δ 8.43% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.14 (Total Current Assets 1.64b - Total Current Liabilities 874.5m) / Total Assets 5.36b |
| B: 0.14 (Retained Earnings 724.0m / Total Assets 5.36b) |
| C: 0.17 (EBIT TTM 787.4m / Avg Total Assets 4.62b) |
| D: 2.92 (Book Value of Equity 3.99b / Total Liabilities 1.37b) |
| Altman-Z'' = 5.58 = AAA |
| DSRI: 1.11 (Receivables 887.0m/595.7m, Revenue 3.37b/2.51b) |
| GMI: 1.01 (GM 98.49% / 97.97%) |
| AQI: 1.48 (AQ_t 0.59 / AQ_t-1 0.40) |
| SGI: 1.34 (Revenue 3.37b / 2.51b) |
| TATA: -0.04 (NI 705.5m - CFO 898.1m) / TA 5.36b) |
| Beneish M = -2.40 (Cap -4..+1) = BBB |
As of August 03, 2026, the stock is trading at USD 166.80 with a total of 4,582,490 shares traded. Over the past week, the price has changed by -5.10%, over one month by -4.28%, over three months by +24.41% and over the past year by +30.27%.
Current recommended Stop Loss: 160.70 (which is 3.7% or 1.2 ATR below the current price).
Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.
- StrongBuy: 15
- Buy: 7
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 202.4 | 21.3% |
P/E Trailing = 27.7695
P/E Forward = 25.5102
P/S = 6.0121
P/B = 5.335
P/EG = 0.5103
Revenue TTM = 3.37b USD
EBIT TTM = 787.4m USD
EBITDA TTM = 817.5m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 401.8m USD (from shortLongTermDebtTotal, last quarter) (leases 406.2m already included)
Net Debt = 12.0m USD (calculated: Debt 401.8m - CCE 389.8m)
Enterprise Value = 18.7b USD (18.7b + Debt 401.8m - CCE 389.8m)
Interest Coverage Ratio = unknown (Ebit TTM 787.4m / Interest Expense TTM 0.0)
EV/FCF = 21.44x (Enterprise Value 18.7b / FCF TTM 870.4m)
FCF Yield = 4.66% (FCF TTM 870.4m / Enterprise Value 18.7b)
FCF Margin = 25.80% (FCF TTM 870.4m / Revenue TTM 3.37b)
Net Margin = 20.91% (Net Income TTM 705.5m / Revenue TTM 3.37b)
Gross Margin = unknown ((Revenue TTM 3.37b - Cost of Revenue TTM 68.6m) / Revenue TTM)
Tobins Q-Ratio = 3.48 (Enterprise Value 18.7b / Total Assets 5.36b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 401.8m)
Taxrate = 24.96% (234.7m / 940.2m)
NOPAT = 590.8m (EBIT 787.4m * (1 - 24.96%))
Current Ratio = 1.87 (Total Current Assets 1.64b / Total Current Liabilities 874.5m)
Debt / Equity = 0.10 (Debt 401.8m / totalStockholderEquity, last quarter 3.99b)
Debt / EBITDA = 0.01 (Net Debt 12.0m / EBITDA 817.5m)
Debt / FCF = 0.01 (Net Debt 12.0m / FCF TTM 870.4m)
Total Stockholder Equity = 3.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.26% (Net Income 705.5m / Total Assets 5.36b)
RoE = 20.67% (Net Income TTM 705.5m / Total Stockholder Equity 3.41b)
RoCE = 17.56% (EBIT 787.4m / Capital Employed (Total Assets 5.36b - Current Liab 874.5m))
RoIC = 13.69% (NOPAT 590.8m / Invested Capital 4.32b)
WACC = 7.57% (E(18.7b)/V(19.1b) * Re(7.73%) + D(401.8m)/V(19.1b) * Rd(0.0%) * (1-Tc(0.25)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.83 | Cagr: 0.26%
[DCF] Terminal Value 77.97% ; FCFF base≈733.7m ; Y1≈841.1m ; Y5≈1.24b
[DCF] Fair Price = 185.1 (EV 18.6b - Net Debt 12.0m = Equity 18.6b / Shares 100.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 86.20 | EPS CAGR: 26.42% | SUE: 1.88 | # QB: 2
Revenue Correlation: 99.42 | Revenue CAGR: 24.37% | SUE: 3.82 | # QB: 5
EPS current Quarter (2026-09-30): EPS=2.71 | Chg30d=-16.17% | Revisions=-25% | Analysts=14
EPS current Year (2026-12-31): EPS=9.93 | Chg30d=-2.46% | Revisions=+25% | GrowthEPS=+55.5% | GrowthRev=+32.6%
EPS next Year (2027-12-31): EPS=12.52 | Chg30d=-0.61% | Revisions=+25% | GrowthEPS=+26.0% | GrowthRev=+18.0%
[Analyst] Revisions Ratio: +17% (up=2, down=1)